BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting
October 12, 2015 at 16:30 PM EDT
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dr. Melita Irving, Clinical Geneticist, Guy's and St Thomas' NHS ...
